KWZL-7f15 (compound 7f15) is a dual CDK6/BET inhibitor with an IC50 of 31.81 nM against human CDK6. KWZL-7f15 inhibits the CDK6-RB axis and the BRD4-Myc axis. KWZL-7f15 exhibits antiproliferative activity against triple-negative breast cancer cells. KWZL-7f15 shows antitumor activity in xenograft mouse models without significant adverse effects. KWZL-7f15 can be used in studies related to triple-negative breast cancer[1].
Molecular Weight:
490.58
Formula:
C26H31FN8O
Target:
Epigenetic Reader Domain
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
